ALXO - מכפיל P/S ALX Oncology

ALX Oncology Holdings (ALXO) competes for market share through safe inhibitors in combination therapy. Development relies on the success of clinical trials and external financing. The brand's high authority is confirmed by the development of efvapcept for combating tumors. The dynamics of the market cap-to-revenue ratio help assess the asset's value, with this metric currently equal to .
ALX Oncology Holdings (ALXO) - פילוחי מדדים ודוחות פיננסיים

This metric is calculated as the ratio of market capitalization to annual revenue, reflecting the cost of each unit of sales. This multiple allows for an assessment of market expectations relative to the business's actual cash flows. For ALX Oncology Holdings (ALXO), during the expansion of Phase II/III clinical trials, the metric serves as an indicator of investor confidence in the future commercial success of its drugs. Analyzing the price-to-sales multiple on the GURU.Markets platform helps identify valuation deviations from the company's fundamental prospects.